Natera, Inc. (NTRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NTRA POWR Grades
- NTRA scores best on the Growth dimension, with a Growth rank ahead of 57.2% of US stocks.
- NTRA's strongest trending metric is Growth; it's been moving up over the last 177 days.
- NTRA ranks lowest in Momentum; there it ranks in the 4th percentile.
NTRA Stock Summary
- With a price/sales ratio of 5.7, NATERA INC has a higher such ratio than 81.28% of stocks in our set.
- Over the past twelve months, NTRA has reported earnings growth of 87.95%, putting it ahead of 83.46% of US stocks in our set.
- The volatility of NATERA INC's share price is greater than that of 82.5% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to NATERA INC, a group of peers worth examining would be LNSR, OCX, NSTG, VRCA, and ONDS.
- NTRA's SEC filings can be seen here. And to visit NATERA INC's official web site, go to www.natera.com.
NTRA Valuation Summary
- In comparison to the median Healthcare stock, NTRA's price/sales ratio is 24.73% higher, now standing at 5.8.
- NTRA's price/sales ratio has moved down 1.1 over the prior 88 months.
Below are key valuation metrics over time for NTRA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NTRA | 2022-09-23 | 5.8 | 9.5 | -7.4 | -8.0 |
| NTRA | 2022-09-22 | 6.2 | 10.1 | -7.8 | -8.4 |
| NTRA | 2022-09-21 | 6.5 | 10.6 | -8.2 | -8.8 |
| NTRA | 2022-09-20 | 6.6 | 10.7 | -8.2 | -8.9 |
| NTRA | 2022-09-19 | 6.6 | 10.7 | -8.2 | -8.9 |
| NTRA | 2022-09-16 | 6.5 | 10.6 | -8.2 | -8.8 |
NTRA Growth Metrics
- Its year over year price growth rate is now at -64.57%.
- Its 5 year cash and equivalents growth rate is now at 193.02%.
- Its year over year net cashflow from operations growth rate is now at -78.88%.
The table below shows NTRA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 723.477 | -437.923 | -575.583 |
| 2022-03-31 | 667.303 | -397.637 | -546.458 |
| 2021-12-31 | 625.486 | -335.236 | -471.716 |
| 2021-09-30 | 564.836 | -309.802 | -407.564 |
| 2021-06-30 | 504.863 | -251.871 | -314.614 |
| 2021-03-31 | 449.309 | -222.288 | -258.225 |
NTRA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NTRA has a Quality Grade of D, ranking ahead of 16.91% of graded US stocks.
- NTRA's asset turnover comes in at 0.553 -- ranking 46th of 81 Healthcare stocks.
- CHE, USPH, and VCYT are the stocks whose asset turnover ratios are most correlated with NTRA.
The table below shows NTRA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.553 | 0.496 | -0.316 |
| 2021-03-31 | 0.510 | 0.498 | -0.272 |
| 2020-12-31 | 0.490 | 0.479 | -0.286 |
| 2020-09-30 | 0.509 | 0.480 | -0.277 |
| 2020-06-30 | 0.609 | 0.472 | -0.279 |
| 2020-03-31 | 0.692 | 0.462 | -0.273 |
NTRA Price Target
For more insight on analysts targets of NTRA, see our NTRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $150.11 | Average Broker Recommendation | 1.35 (Strong Buy) |
NTRA Stock Price Chart Interactive Chart >
NTRA Price/Volume Stats
| Current price | $44.35 | 52-week high | $121.05 |
| Prev. close | $43.82 | 52-week low | $26.10 |
| Day low | $43.04 | Volume | 121,069 |
| Day high | $44.66 | Avg. volume | 1,749,663 |
| 50-day MA | $49.29 | Dividend yield | N/A |
| 200-day MA | $50.65 | Market Cap | 4.30B |
Natera, Inc. (NTRA) Company Bio
Natera Inc. is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The company was founded in 2003 and is based in San Carlos, California.
Latest NTRA News From Around the Web
Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Natera Announces 2025 ESG Goals with Publication of 2021 ReportNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company's commitment to environmental sustainability, social equity and improved access to health care. The report, which can be found here, includes the company's 2025 ESG Goals. |
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant SettingsNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France. |
Natera to Participate in Upcoming Investor ConferencesNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the following upcoming investor conferences: |
Natera Earns Great Place to Work Certification™ for Second Consecutive YearNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year. The certification is based entirely on how current employees rate their experience working at Natera in an independently administered, anonymous survey. |
Natera Announces Enrollment Completion for RenaCARE StudyNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight™ genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis. The study includ |
NTRA Price Returns
| 1-mo | -6.93% |
| 3-mo | 14.33% |
| 6-mo | 4.87% |
| 1-year | -60.54% |
| 3-year | 25.04% |
| 5-year | 221.84% |
| YTD | -52.51% |
| 2021 | -6.16% |
| 2020 | 195.40% |
| 2019 | 141.33% |
| 2018 | 55.28% |
| 2017 | -23.23% |
Continue Researching NTRA
Here are a few links from around the web to help you further your research on Natera Inc's stock as an investment opportunity:Natera Inc (NTRA) Stock Price | Nasdaq
Natera Inc (NTRA) Stock Quote, History and News - Yahoo Finance
Natera Inc (NTRA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...